A mechanistic multi-centre, parallel group, randomised placebo controlled trial of Mesalazine for treatment of irritable bowel syndrome with diarrhoea (IBS-D)

A mechanistic multi-centre, parallel group, randomised placebo controlled trial of Mesalazine for treatment of irritable bowel syndrome with diarrhoea (IBS-D)

Introduction: Immune activation has been reported in the mucosa of irritable bowel syndrome patients with diarrhoea (IBS-D) and some small studies have suggested that Mesalazine may reduce symptoms. We performed a double blind, randomised placebo controlled trial of 2g Mesalazine twice daily versus...

Full description

Bibliographic Details
Main Authors: Lam, Ching, Tan, Wei, Leighton, Matthew, Hastings, Margaret, Lingaya, Melanie, Falcone, Yirga, Zhou, Xiaoying, Xu, Luting, Whorwell, Peter, Walls, Andrew, Zaitoun, Abed M., Montgomery, Alan, Spiller, Robin C.
Format: Article
Published: BMJ Publishing Group 2015
Subjects:
irritable bowel syndrome
diarrhoea
5-aminosalicylate acid
Online Access:https://eprints.nottingham.ac.uk/40150/

Internet

https://eprints.nottingham.ac.uk/40150/

Similar Items